



MICROVENTION'S HYDROCOIL® EMBOLIC SYSTEM WAS FOCUS OF NINE SCIENTIFIC PRESENTATIONS AT RECENT INTERNATIONAL CONFERENCES

Preliminary Data Shows Promise for Expandable Hydrogel Technology in Treatment of Cerebral Aneurysms

ALISO VIEJO, Calif. – June 6, 2005 – MicroVention, Inc., a leading developer, manufacturer and marketer of minimally invasive treatments for cerebral and peripheral vascular diseases, announced today that the positive effects of its innovative HydroCoil Embolic System (HydroCoil System) for treating brain aneurysms were the focus of nine scientific presentations at two symposiums during consecutive international conferences in May. The HydroCoil System is a unique device that uses an expandable polymer to generate up to 11 times the volumetric dimensions compared to platinum coils, allowing physicians to more effectively fill a cerebral aneurysm, a potentially deadly bulge or sac in the wall of an artery in the brain.

Among the highlights of the presentations were updates on two ongoing studies that compare the results derived from the HydroCoil System to results from bare platinum coils, which is the first generation technology for endovascular aneurysm therapy. The two conferences were held in Toronto from May 20-27 and sponsored by the American Society for Interventional Therapeutic Neuroradiology (ASITN) and the American Society for Neuroradiology (ASNR).

“We firmly believe our HydroCoil System provides more durable results for patients with aneurysms than bare platinum coils, which is a major reason we have initiated these head-to-head studies,” said Mike Kleine, President and CEO of MicroVention. “Unlike platinum, our hydrogel technology is microporous and expandable, which is what the physician community is telling us is needed for improved clinical outcomes. The data compiled so far in these studies is impressive and we look forward to sharing the results as they progress.”

In an update of an ongoing multi-center study of patients treated with the HydroCoil System comprising 219 patients with 128 follow-ups of at least six months, Harish Shownkeen, M.D., and Noel Fanning, M.D., both interventional neuroradiologists participating in the study, noted that the HydroCoil System demonstrated an initial retreatment rate of 4.5 percent which is approximately three times lower than the retreatment rate for bare platinum coils. More specifically, in patients having an aneurysm smaller than 10 millimeters in diameter, which represents approximately 75 percent of the market, the retreatment rate thus far was zero.

An additional update was presented by Philip White, M.D., of Western General Hospital in Edinburgh, the chief investigator of the HydroCoil Endovascular Aneurysm Occlusion and Packing Study (HELPS). Dr. White noted that this clinical trial is the only one of its kind and that 75 of the targeted 500 patients from more than 20 sites around the world are already enrolled. Dr. White further noted that the results of this blinded, physician-designed, randomized, multi-center, prospective study will be analyzed by an independent group of experts and periodic clinical updates provided throughout the remainder of 2005 and 2006 until the HELPS study is completed.

About MicroVention, Inc.

MicroVention, Inc. (www.microvention.com) is a privately held medical-device company dedicated to the development and commercialization of new catheter-based technologies for the endovascular treatment of peripheral and cerebral vascular diseases. The company has received 510(k) clearance and CE Mark for both its HydroCoil Embolic System and the MicroPlex® Coil System to treat cerebral aneurysms and other vascular lesions. MicroVention sells its products through its direct sales force in the U.S., Canada, France, Germany and the United Kingdom and through distributors in numerous other countries.

MicroVention Contacts:

Chris Owens, VP Worldwide Marketing
Rob Greene, VP Research & Development
Ph. 949-461-3314
Fx. 949-461-3329

Matt Clawson (Media)
Allen & Caron, Inc.
Ph. 949-474-4300
Fx. 949-474-4330